Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2002
07/04/2002WO2001098275A3 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
07/04/2002WO2001092213A3 Excitatory amino acid receptor modulators
07/04/2002WO2001091715A3 Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-d-glucopyranoside
07/04/2002WO2001091535A3 A combination kit used in the treatment of malaria containing chloroquine and 3-(1-(((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3h)furanone enthält
07/04/2002WO2001082916A3 Combination therapeutic compositions and methods of use
07/04/2002WO2001078779A3 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
07/04/2002WO2001078711A3 Pde-v inhibitors for treatment of parkinson's disease
07/04/2002WO2001077097A3 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
07/04/2002WO2001068855A3 Gtp-binding protein gamma-12 subunit
07/04/2002WO2001068080A3 Neutral antagonists and use thereof in treating drug abuse
07/04/2002WO2001062257A3 Bupropion metabolites and methods of their synthesis and use
07/04/2002WO2001046420A8 Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
07/04/2002WO2001046176A3 Non peptide tachykinin receptor antagonists
07/04/2002WO2001045692A9 Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
07/04/2002WO2001044260A9 Novel purines
07/04/2002WO2001041535A9 Eplerenone crystalline form
07/04/2002WO2001036007A3 Compositions of a combination of radioactive therapy and cell-cycle inhibitors
07/04/2002WO2001034099A9 Soy depigmenting and skin care compositions
07/04/2002WO2001032183A3 Pharmaceutical compositions comprising oxcarbazepine
07/04/2002WO2001028551A9 Agents for promoting fattening of animals and method of promoting fattening
07/04/2002WO2001016096A3 Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia
07/04/2002WO2000076510A9 Dermal anesthetic agents
07/04/2002WO2000075116A3 Tricyclic analgesics
07/04/2002WO2000074687A9 Antisense modulation of b7 protein expression
07/04/2002US20020087205 Transcutaneous photodynamic treatment of targeted cells
07/04/2002US20020087013 Methods for preparing new taxoids and pharmaceutical compositions containing them
07/04/2002US20020087011 Improved process and novel intermediates to endothelin receptor antagonists
07/04/2002US20020087009 Intermediates for (r)-3(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-h-imidazo[1,2-a] imidazol-2-one
07/04/2002US20020087005 Process for the preparation of non-steroidal glucocorticoid receptor modulators
07/04/2002US20020087002 Naphthalenyl piperidines as renin inhibitors
07/04/2002US20020087001 Antipsychotic activity but no cataleptic effects, not induce extrapyramidal side effects; 1-(4-(4-((4-fluorophenyl) (4-methylthien-2-yl)methylene)piperidin-1-yl)-1-oxobutyl)-piperidine salt for example
07/04/2002US20020086999 Certain quinoline derivatives
07/04/2002US20020086996 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates
07/04/2002US20020086995 Recrystallizing mercaptoalkanoylamino lactam acid under basic conditions using an agent that minimizes amount of disulfides
07/04/2002US20020086994 Deprotection processes
07/04/2002US20020086987 Nucleotide sequence coding human protein for use in treatment of osteoporosis and bone disorders
07/04/2002US20020086906 Drugs, cosmetics or dietary supplements; immunomodulation, antiallergens (IgE mediated allergies, e.g., asthma, rhinitis, eczema); anaphylaxis; autoimmune disorders, e.g., Crohn's disease, antiarthritic and ulcer agents; analgesics
07/04/2002US20020086905 Gel for treatment of skin diseases and for disinfection of the skin
07/04/2002US20020086904 Methods of treating affective disorders using derivatives of (-)- venlafaxine
07/04/2002US20020086900 Methods of producing oxazolidinone compounds
07/04/2002US20020086899 Treatment of neurotic disorders
07/04/2002US20020086897 Cytotoxic agents comprising taxanes and their therapeutic use
07/04/2002US20020086896 Inhibiting stenosis or restenosis following vascular trauma in a mammalian host with cytoskeletal inhibitor comprising taxol, cytochalasin, or an analog thereof; implant coated or embedded with inhibitors for sustained release
07/04/2002US20020086895 Methods of treating fungal infections
07/04/2002US20020086894 Namely rofecoxib and lovastatin, respectively, with a glutathione pathway enhancing and detoxifying compound, cystine; treatment of prostate or pancreatic cancer by selectively weakening cancer cells via cholesterol pathways
07/04/2002US20020086893 Imidazole based angiotensin II receptor antagonist for treating haemorrhagic stroke
07/04/2002US20020086891 Substituted benzo(b)thiophenes or benzoisothiazoles which inhibit 2,3-oxidosqualene-lanosterol cyclase which is required for the biosynthesis of cholesterol, ergosterol and other sterols
07/04/2002US20020086890 Inhibitors of TNF-alpha converting enzyme; treatment of arthritis, inflammation, inflammatory bowel disease etc,
07/04/2002US20020086889 Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
07/04/2002US20020086888 Substantially free from amlodipine aspartate side products, by reacting amlodipine or an acid addition salt thereof with excess maleic acid under acidic environment
07/04/2002US20020086887 N-Acylsulfonamide apoptosis promoters
07/04/2002US20020086886 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
07/04/2002US20020086885 Pharmaceutical composition
07/04/2002US20020086884 Anticancer agents based on regulation of protein prenylation
07/04/2002US20020086883 Compound, such as pioglitazone, having an insulin sensitivity enhancing activity for the prophylaxis or treatment of a disease mediated by promotion of apoptosis, such as neurodegenerative disease
07/04/2002US20020086881 As well as 5-HT3 antagonists and 5-HT4 agonists; for preventing or managing gastro-esophageal reflux disease and/or emesis
07/04/2002US20020086880 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
07/04/2002US20020086879 Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
07/04/2002US20020086878 Monomolecular dispersions of various medicaments prepared for transmucosal delivery; treatment of respiratory illness such as cold and/or allergy
07/04/2002US20020086877 Matrix metalloproteinase inhibitors
07/04/2002US20020086876 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
07/04/2002US20020086875 Use of nicergoline in the treatment of spasticity
07/04/2002US20020086874 Substituted indoline derivative compounds which are antagonists of the progesterone receptor; contraceptives; antineoplastic agents
07/04/2002US20020086872 Anticoagulants; may be embedded in or physically linked to materials used in manufacture of devices used in blood collection, circulation, stents
07/04/2002US20020086871 Pharmaceutical composition for the treatment of CNS and other disorders
07/04/2002US20020086870 Pharmacological treatment for sleep apnea
07/04/2002US20020086869 Treatment of inflammation, arthritis, bone disorders, respiratory system disorders
07/04/2002US20020086868 Methods of use of gemifloxacin compounds against fluoroquinolone resistant Streptococcus pneumoniae bacteria
07/04/2002US20020086867 Using gemifloxacin compound
07/04/2002US20020086866 Quinoxalinones as serine protease inhibitors
07/04/2002US20020086865 Use of growth hormone secretagogues for stimulating or increasing appetite
07/04/2002US20020086864 Administering optically pure (S,S) enantiomer of reboxetine
07/04/2002US20020086862 1,2,4-triazole-3-thione compounds; treatment of disorders such as ischaemia, psoriasis
07/04/2002US20020086860 For treatment or prevention of disorders such as obsessive-compulsive disorder, depression, anxiety, schizophrenia
07/04/2002US20020086859 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
07/04/2002US20020086858 Neuropeptide Y antagonists; treatment of eating disorders such as obesity and hyperphagia
07/04/2002US20020086857 Method of long-term treatment of graft-versus-host disease using topical active corticosterioids
07/04/2002US20020086856 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
07/04/2002US20020086855 Medicament for treating obesity and improving lipid metabolism
07/04/2002US20020086854 Methods and compositions using norastemizole in combination with leukotriene inhibitors
07/04/2002US20020086852 Method for treating respiratory disorders associated with pulmonary elastic fiber injury
07/04/2002US20020086850 Antiinflammatory agents
07/04/2002US20020086849 Method for introducing antisense oligonucleotides into eucaryotic cells
07/04/2002US20020086845 Rat PTTG polypeptide and method for producing it
07/04/2002US20020086839 Inhibitors of DNA immunostimulatory sequence activity
07/04/2002US20020086838 Such as antibodies, proteins, drugs such as spironolactone, imidapril, an angiotensin converting enzyme inhibitor, captopril, enalapril, defibrotide, and angiotensin II receptor antagonist
07/04/2002US20020086836 Cftr gene regulator
07/04/2002US20020086835 Inhibitors such as pentostatin
07/04/2002US20020086834 Flavonoid glycoside of given formula; extract of Cassia alata
07/04/2002US20020086833 Cocoa procyanidin oligomer/polymer, a polyphenol-type compound; anticancer agent; antioxidant; DNA topoisomerase II enzyme inhibitors, cyclooxygenase, NO (Nitric Oxide) or NO-synthase modulators, nonsteroidal antiinflammatory agent
07/04/2002US20020086828 Uses for amino acid anticonvulsants
07/04/2002US20020086822 Nucleic acids, proteins, and antibodies
07/04/2002US20020086818 Combination therapy including 9-nitro-20(S)-camptothecin and 5-fluorouracil
07/04/2002US20020086815 Cancer therapy; for skin cancer, myeloids
07/04/2002US20020086811 Nucleic acids, proteins, and antibodies
07/04/2002US20020086420 Novel antiangiogenic peptides
07/04/2002US20020086414 Novel ctla4/cd28 ligands and uses therefor
07/04/2002US20020086380 Enzymatic polypeptide for use in animal feeds and in generating chemical intermediates for vitamin A
07/04/2002US20020086360 Polypeptide for use in treatment of congestive heart failure, ischaemic heart defects, arrhytmias, cardioiomyopathy and stroke
07/04/2002US20020086356 Preferential nucleotide sequences for controlling preferential ribonucleic acids; for use in therapeutic genomics; for gene therapy